OM
PTCT icon

Opaleye Management’s PTC Therapeutics PTCT Stock Holding History

Opaleye Management’s Portfolio PTCT Stock Details PTCT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q1 		– Sell
-191,000
Closed -$9.17M – 49
2019
Q4 		$9.17M Buy
191,000
+1,000
+0.5% +$42.5K 1.8% 24
2019
Q3 		$6.43M Sell
190,000
-36,388
-16% -$1.58M 2.32% 22
2019
Q2 		$10.2M Buy
226,388
+12,588
+6% +$497K 3.1% 12
2019
Q1 		$8.05M Buy
213,800
+23,800
+13% +$799K 2.23% 17
2018
Q4 		$6.52M Buy
190,000
+10,000
+6% +$360K 2.43% 10
2018
Q3 		$8.46M Hold
180,000
– – 2.15% 13
2018
Q2 		$6.07M Buy
180,000
+35,000
+24% +$1.09M 1.57% 25
2018
Q1 		$3.92M Buy
+145,000
New +$3.67M 1.12% 27

Other funds holding PTCT

Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London $209B AUM 37.72% 1-Year Est. Return
GPP
Great Point Partners Greenwich, Connecticut $529M AUM 337.4% 1-Year Est. Return

Opaleye Management's PTCT Position: Q1 2020 in Review

Opaleye Management sold out of PTC Therapeutics (PTCT) in Q1 2020, closing a stake of 191,000 shares — an estimated $9.17M sold.

Opaleye Management first reported a position in PTCT in Q1 2018 and held it in 8 quarters. The position peaked at $10.2M in Q2 2019. 203 funds tracked by Wall St. Rank hold PTCT as of Q1 2020.

  • Opaleye Management reported no remaining PTC Therapeutics position as of Q1 2020 after selling out during the quarter.
  • Opaleye Management sold 191,000 PTC Therapeutics shares in Q1 2020, an estimated $9.17M.
  • Opaleye Management first reported a position in PTC Therapeutics in Q1 2018 and held it in 8 quarters.
  • Opaleye Management's PTC Therapeutics position peaked at $10.2M in Q2 2019.
  • 203 funds tracked by Wall St. Rank held PTC Therapeutics as of Q1 2020.

Based on Opaleye Management's 13F filing for Q1 2020, filed 15 May 2020.